<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35239247</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurological outcomes 1&#xa0;year after COVID-19 diagnosis: A prospective longitudinal cohort study.</ArticleTitle><Pagination><StartPage>1685</StartPage><EndPage>1696</EndPage><MedlinePgn>1685-1696</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15307</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Neurological sequelae from coronavirus disease 2019 (COVID-19)&#xa0;may persist after recovery from acute infection. Here, the aim was to describe the natural history of neurological manifestations over 1&#xa0;year after COVID-19.</AbstractText><AbstractText Label="METHODS">A prospective, multicentre, longitudinal cohort study in COVID-19&#xa0;survivors was performed. At a 3-month and 1-year follow-up, patients were assessed for neurological impairments by a neurological examination and a standardized test battery including the assessment of hyposmia (16-item Sniffin' Sticks test), cognitive deficits (Montreal Cognitive Assessment &lt; 26) and mental health (Hospital Anxiety and Depression Scale and Post-traumatic Stress Disorder Checklist 5).</AbstractText><AbstractText Label="RESULTS">Eighty-one patients were evaluated 1&#xa0;year after COVID-19, out of which 76 (94%) patients completed a 3-month and 1-year follow-up. Patients were 54 (47-64) years old and 59% were male. New and persistent neurological disorders were found in 15% (3 months) and 12% (10/81; 1 year). Symptoms at 1-year follow-up were reported by 48/81 (59%) patients, including fatigue (38%), concentration difficulties (25%), forgetfulness (25%), sleep disturbances (22%), myalgia (17%), limb weakness (17%), headache (16%), impaired sensation (16%) and hyposmia (15%). Neurological examination revealed findings in 52/81 (64%) patients without improvement over time (3 months, 61%, p&#xa0;=&#xa0;0.230) including objective hyposmia (Sniffin' Sticks test &lt;13; 51%). Cognitive deficits were apparent in 18%, whereas signs of depression, anxiety and post-traumatic stress disorders were found in 6%, 29% and 10% respectively 1&#xa0;year after infection. These mental and cognitive disorders had not improved after the 3-month follow-up (all p&#xa0;&gt;&#xa0;0.05).</AbstractText><AbstractText Label="CONCLUSION">Our data indicate that a significant patient number still suffer from neurological sequelae including neuropsychiatric symptoms 1&#xa0;year after COVID-19&#xa0;calling for interdisciplinary management of these patients.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rass</LastName><ForeName>Verena</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4241-5891</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beer</LastName><ForeName>Ronny</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiefecker</LastName><ForeName>Alois Josef</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindner</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0622-8033</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kofler</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3800-8417</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ianosi</LastName><ForeName>Bogdan Andrei</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0003-0705-4901</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahlknecht</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0671-0516</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heim</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6749-3044</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peball</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carbone</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limmert</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kindl</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putnina</LastName><ForeName>Lauma</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fava</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahanic</LastName><ForeName>Sabina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonnweber</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;scher</LastName><ForeName>Wolfgang N</ForeName><Initials>WN</Initials><Identifier Source="ORCID">0000-0002-7593-3222</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanschitz</LastName><ForeName>Julia V</ForeName><Initials>JV</Initials><Identifier Source="ORCID">0000-0002-0207-9977</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamarian</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1640-4179</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djamshidian</LastName><ForeName>Atbin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7174-6000</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tancevski</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>G&#xfc;nter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellmann-Weiler</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiechl</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seppi</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loeffler-Ragg</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfausler</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helbok</LastName><ForeName>Raimund</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5682-0145</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="N">Anosmia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neurological manifestations</Keyword></KeywordList><CoiStatement>KS reports grants from FWF Austrian Science Fund, grants from Michael J. Fox Foundation, grants from International Parkinson and Movement Disorder Society, personal fees from Teva, personal fees from UCB, personal fees from Lundbeck, personal fees from AOP Orphan Pharmaceuticals AG, personal fees from Abbvie, personal fees from Roche, personal fees from Gr&#xfc;nenthal; all outside the submitted work. PM reports grants from TWF (Tyrolean Science Fund), grants from Medtronic, personal fees from Boston Scientific, all outside the submitted work. The other authors have nothing to disclose. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35239247</ArticleId><ArticleId IdType="pmc">PMC9111823</ArticleId><ArticleId IdType="doi">10.1111/ene.15307</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID&#x2010;19. Lancet Neurol. 2020;19:767&#x2010;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of COVID&#x2010;19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136.</Citation><ArticleIdList><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou SH, Beghi E, Helbok R, et al. Global incidence of neurological manifestations among patients hospitalized with COVID&#x2010;19&#x2014;a report for the GCS&#x2010;NeuroCOVID consortium and the ENERGY consortium. JAMA Netw Open. 2021;4:e2112131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8114143</ArticleId><ArticleId IdType="pubmed">33974053</ArticleId></ArticleIdList></Reference><Reference><Citation>Rass V, Beer R, Schiefecker AJ, et al. Neurological outcome and quality of life 3 months after COVID&#x2010;19: a prospective observational cohort study. Eur J Neurol. 2021;28:3348&#x2010;3359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250725</ArticleId><ArticleId IdType="pubmed">33682276</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, Helbok R, Crean M, et al. The European Academy of Neurology COVID&#x2010;19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID&#x2010;19. Eur J Neurol. 2021;28:3303&#x2010;3323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753513</ArticleId><ArticleId IdType="pubmed">33220127</ArticleId></ArticleIdList></Reference><Reference><Citation>Crispo A, Bimonte S, Porciello G, et al. Strategies to evaluate outcomes in long&#x2010;COVID&#x2010;19 and post&#x2010;COVID survivors. Infect Agent Cancer. 2021;16:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556851</ArticleId><ArticleId IdType="pubmed">34717691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez&#x2010;Leon S, Wegman&#x2010;Ostrosky T, Perelman C, et al. More than 50 long&#x2010;term effects of COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Sci Rep. 2021;11:16144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1&#x2010;year outcomes in hospital survivors with COVID&#x2010;19: a longitudinal cohort study. Lancet. 2021;398:747&#x2010;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnweber T, Sahanic S, Pizzini A, et al. Cardiopulmonary recovery after COVID&#x2010;19: an observational prospective multicentre trial. Eur Respir J. 2021;57:2003481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736754</ArticleId><ArticleId IdType="pubmed">33303539</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SJ, Bellmann R, Dejaco H, et al. Structured ICU resource management in a pandemic is associated with favorable outcome in critically ill COVID&#x2010;19 patients. Wien Klin Wochenschr. 2020;132:653&#x2010;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7653454</ArticleId><ArticleId IdType="pubmed">33170333</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, Kobal G, Gudziol H, Mackay&#x2010;Sim A. Normative data for the "Sniffin&#x2019; Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol. 2007;264:237&#x2010;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">17021776</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695&#x2010;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard EB, Jones&#x2010;Alexander J, Buckley TC, Forneris CA. Psychometric properties of the PTSD checklist (PCL). Behav Res Ther. 1996;34:669&#x2010;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">8870294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann C, Buss U, Snaith RP. Hospital anxiety and depression scale &#x2010; German version (HADS&#x2010;D). Huber; 1995.</Citation></Reference><Reference><Citation>Hansson M, Chotai J, Nordstom A, Bodlund O. Comparison of two self&#x2010;rating scales to detect depression: HADS and PHQ&#x2010;9. Br J Gen Pract. 2009;59:e283&#x2010;e288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734374</ArticleId><ArticleId IdType="pubmed">19761655</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS). Br J Health Psychol. 2004;9:279&#x2010;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">15296678</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp LB, LaRocca NG, Muir&#x2010;Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121&#x2010;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">2803071</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerdal A, Wahl A, Rustoen T, Hanestad BR, Moum T. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand J Public Health. 2005;33:123&#x2010;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823973</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27:601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL. Advances in understanding the pathophysiology of chronic fatigue syndrome. JAMA. 2019;322:499&#x2010;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">31276153</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, et al. Post&#x2010;infective and chronic fatigue syndromes precipitated by viral and non&#x2010;viral pathogens: prospective cohort study. BMJ. 2006;333:575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID&#x2010;19 lead to myalgic encephalomyelitis/chronic fatigue syndrome? Front Med (Lausanne). 2020;7:606824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan R, Zhang Q, Anthony SM, et al. Oligodendrocytes that survive acute coronavirus infection induce prolonged inflammatory responses in the CNS. Proc Natl Acad Sci USA. 2020;117:15902&#x2010;15910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7355048</ArticleId><ArticleId IdType="pubmed">32571951</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon DC, Ho YS, Chiu K, Wong HL, Chang RC. Sickness: from the focus on cytokines, prostaglandins, and complement factors to the perspectives of neurons. Neurosci Biobehav Rev. 2015;57:30&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">26363665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurz K, Schroecksnadel S, Weiss G, Fuchs D. Association between increased tryptophan degradation and depression in cancer patients. Curr Opin Clin Nutr Metab Care. 2011;14:49&#x2010;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">21076293</ArticleId></ArticleIdList></Reference><Reference><Citation>Muccioli L, Pensato U, Cani I, Guarino M, Cortelli P, Bisulli F. COVID&#x2010;19&#x2010;associated encephalopathy and cytokine&#x2010;mediated neuroinflammation. Ann Neurol. 2020;88:860&#x2010;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">32715524</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long&#x2010;term consequences of COVID&#x2010;19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271826</ArticleId><ArticleId IdType="pubmed">32498691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindlau A, Widmann CN, Putensen C, Jessen F, Semmler A, Heneka MT. Predictors of hippocampal atrophy in critically ill patients. Eur J Neurol. 2015;22:410&#x2010;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">24724819</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long&#x2010;term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787&#x2010;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3345288</ArticleId><ArticleId IdType="pubmed">20978258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandnes M, Ulvik RJ, Vorland M, Reikvam H. Hyperferritinemia&#x2014;a clinical overview. J Clin Med. 2021;10:2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8125175</ArticleId><ArticleId IdType="pubmed">34067164</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID&#x2010;19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2010;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmann&#x2010;Weiler R, Lanser L, Barket R, et al. Prevalence and predictive value of anemia and dysregulated iron homeostasis in patients with COVID&#x2010;19 infection. J Clin Med. 2020;9:2429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7464087</ArticleId><ArticleId IdType="pubmed">32751400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnweber T, Boehm A, Sahanic S, et al. Persisting alterations of iron homeostasis in COVID&#x2010;19 are associated with non&#x2010;resolving lung pathologies and poor patients&#x2019; performance: a prospective observational cohort study. Respir Res. 2020;21:276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7575703</ArticleId><ArticleId IdType="pubmed">33087116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202:415&#x2010;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213088</ArticleId><ArticleId IdType="pubmed">16043521</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS&#x2010;CoV&#x2010;2 infection. N Engl J Med. 2020;382:2268&#x2010;2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift AK, von Ende A, Tan PS, et al. Smoking and COVID&#x2010;19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort. Thorax. 2021;77(1):65&#x2010;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8483921</ArticleId><ArticleId IdType="pubmed">34580193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke J, Hollander K, Mohr L, et al. Drastic reductions in mental well&#x2010;being observed globally during the COVID&#x2010;19 pandemic: results from the ASAP survey. Front Med (Lausanne). 2021;8:578959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8032868</ArticleId><ArticleId IdType="pubmed">33842492</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira C, Rosa RG, Sganzerla D, et al. The burden of mental illness among survivors of critical care&#x2014;risk factors and impact on quality of life: a multicenter prospective cohort study. Chest. 2021;160(1):157&#x2010;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">33640377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokkoku K, Erra C, Cuccagna C, et al. Intensive care unit&#x2010;acquired weakness and positioning&#x2010;related peripheral nerve injuries in COVID&#x2010;19: a case series of three patients and the latest literature review. Brain Sci. 2021;11:1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8470888</ArticleId><ArticleId IdType="pubmed">34573198</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai JP, Baker AJ. Influenza&#x2010;associated neurological complications. Neurocrit Care. 2013;18:118&#x2010;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">23138546</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6&#x2010;month neurological and psychiatric outcomes in 236 379 survivors of COVID&#x2010;19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416&#x2010;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanjanaumporn J, Aeumjaturapat S, Snidvongs K, Seresirikachorn K, Chusakul S. Smell and taste dysfunction in patients with SARS&#x2010;CoV&#x2010;2 infection: a review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pac J Allergy Immunol. 2020;38:69&#x2010;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">32563234</ArticleId></ArticleIdList></Reference><Reference><Citation>Desiato VM, Levy DA, Byun YJ, Nguyen SA, Soler ZM, Schlosser RJ. The prevalence of olfactory dysfunction in the general population: a systematic review and meta&#x2010;analysis. Am J Rhinol Allergy. 2021;35:195&#x2010;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">32746612</ArticleId></ArticleIdList></Reference><Reference><Citation>Damm M, Pikart LK, Reimann H, et al. Olfactory training is helpful in postinfectious olfactory loss: a randomized, controlled, multicenter study. Laryngoscope. 2014;124:826&#x2010;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">23929687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummel T, Rissom K, Reden J, Hahner A, Weidenbecher M, Huttenbrink KB. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009;119:496&#x2010;499.</Citation><ArticleIdList><ArticleId IdType="pubmed">19235739</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinidis I, Tsakiropoulou E, Bekiaridou P, Kazantzidou C, Constantinidis J. Use of olfactory training in post&#x2010;traumatic and postinfectious olfactory dysfunction. Laryngoscope. 2013;123:E85&#x2010;E90.</Citation><ArticleIdList><ArticleId IdType="pubmed">24114690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>